Wunder Mobility Launches Its Own Sharing Ready E-Bike Co-developed With Yadea
29.10.2021 09:30:00 EEST | Business Wire | Press release
Wunder Mobility, the international provider of software and hardware for new mobility services, has launched its first co-developed e-bike. Unveiled at the Wunder Mobility Summit 2021, the new bike has been designed in partnership with Yadea, specifically for shared use. It boasts an industry-topping range of 120km, comes with a speed of 25 km/h, and is specifically designed for European markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028006347/en/
Wunder Mobility's new e-bike has been designed in partnership with Yadea, specifically for shared use.
The e-bike’s launch follows the recent IPCC Intergovernmental Panel on Climate Change Sixth Assessment Report which drastically shows that CO2 emissions must be substantially reduced.
As an environmentally friendly mode of transport, bike-sharing is expected to grow 11% worldwide by 2025. During COVID-19, spurred on by booming consumer demand, many city authorities have increased their efforts to make their cities more bike-friendly. Initiatives include pop-up lanes and new cycleways. Political commitments to a transition to the Green Economy continue to drive investment in cycling infrastructure.
Working with Yadea, the world’s largest manufacturer of electric two-wheel vehicles, Wunder Mobility's own e-bike is a leap forward in design to help shared mobility operators capitalise on increasing opportunity. The companies are building on their long-standing relationship with Wunder Mobility’s software integrating with Yadea vehicles since 2019.
Taking shared e-bike performance to the next level
This is the first time an e-bike has been co-designed with Wunder Mobility’s technology and insight at its core. It combines Wunder Mobility’s data-driven understanding of the needs of operators and their users with Yadea’s market leadership in design and manufacturing.
With a range of 120km the e-bike far exceeds the industry average of 70-80km and is based on rider biometrics which best fit the European market. It is equipped with a motor lock and a smart lock for dual security – a rear wheel cover enclosing the locking mechanism to prevent tampering and offering space for marketing purposes. A swappable battery, firmware updates over the air and a built-in IoT connector which comes with Wunder Mobility software provide further ease of use for operators.
Gunnar Froh, Founder and Chief Executive Officer of Wunder Mobility, said:
“Cycling is one of the key solutions for reducing mobility emissions. Through our collaboration we have produced a better performing e-bike for both the operator and the cyclist. This will play a vital role in helping cities and their citizens to achieve green goals and boost wellbeing through exercise. Superior range, weight and security coupled to our powerful platform will enable more short city journeys and cleaner and healthier longer distance urban travel.”
Heidi Zang, Overseas Director at Yadea, said:
“The extensive market research, analysis and design development behind this e-bike has deepened our close collaboration with the team at Wunder Mobility. A market-dominating high range, low weight and uncomplicated maintenance sets new standards and complements the product portfolio of environmentally friendly urban mobility solutions. The simple and smooth design is unique in the sharing field, attracting consumers' attention and encouraging them to choose this e-bike.”
ENDS
Yadea:
Yadea is a global leader in developing and manufacturing electric two-wheel vehicles including electric motorcycles, electric mopeds, electric bicycles and electric kick scooters. Yadea's mission is to use its market leadership to inspire a movement towards greener travel solutions and its vision is to create world-leading electric vehicle solutions by building innovative technologies that meet and exceed international standards for safety and quality.
For more information: www.yadea.com.
Wunder Mobility:
Wunder Mobility is the global leader in software and hardware for new mobility services. The mobility tech company provides white-label solutions that enable enterprises, startups and cities worldwide to deliver sustainable, convenient and secure mobility.
100+ customers in over 900 cities on six continents use the Wunder Mobility platform to launch and scale new mobility services, manage and finance shared vehicle fleets, optimize daily operations, and improve urban planning and traffic management.
The global Wunder Mobility team, with more than 40 nationalities, consists of technology and mobility industry veterans. 50% of the team is in Product and Engineering. Wunder Mobility was founded in 2014 by Gunnar Froh and Sam Baker. The headquarters are in Hamburg, with additional locations in Dortmund and Los Angeles. For more information:
www.wundermobility.com | LinkedIn | Twitter | YouTube | Wunder Mobility Podcast
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028006347/en/
Contact information
Press contact
WunderCar Mobility Solutions GmbH
Marius Koch
Mail: press@wundermobility.com
Tel: +49 1515 339 1834
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
